File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: 48 Weeks pegylated interferon alfa-2a is superior to 24 weeks of pegylated interferon alfa-2b in achievingHBeAg seroconversion in chronic hepatitis B infection

Title48 Weeks pegylated interferon alfa-2a is superior to 24 weeks of pegylated interferon alfa-2b in achievingHBeAg seroconversion in chronic hepatitis B infection
Authors
Issue Date2006
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Wiley-Blackwell Publishing Asia
Citation
Shanghai—Hong Kong International Liver Congress, Shanghai, China, 25–28 March 2006. In Journal of Gastroenterology and Hepatology, 2006, v. 21 n. S2, p. A90 How to Cite?
AbstractBackground/Aim Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronichepatitis B virus (HBV) infection, the efficacy of a shorter durationof therapy with pegylated interferons is unknown.Method We retrospectively compared the efficacy of 48 weeks treat-ment with pegylated-interferon-alfa-2a to a 24-week regime withpegylated-interferon-alfa-2b in 53 hepatitis B e antigen (HBeAg) positive Chinese patients. Sustained virological response (SVR) wasdefined as HBeAg seroconversion and HBV DNA less than 105copies/ml at 24 weeks after the end-of-therapy (EFU).Results Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alfa-2a and 24 patients with 24 weeks of pegylated-interferon-alfa-2b. The baseline characteristics were com-parable between the 2 groups. At the end-of-therapy, 9 of the 29patients (31.0%) treated with 48 weeks of pegylated-interferon-alfa-2a compared with 2 of the 24 patients (8.3%) treated with 24weeks of pegylated-interferon-alfa-2b had HBeAg seroconversion andHBV DNA less than 105 copies/ml (p = 0.09). At the EFU, 10 of the29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alfa-2a compared with 2 of the 24 patients (8.3%) treated with 24weeks of pegylated-interferon-alfa-2b had SVR (p = 0.04). There wasno withdrawals from treatment in both groups. Adverse events werecomparable between the 2 groups.Conclusion A 48-week course of pegylated-interferon may be asso-ciated with a higher SVR when compared with 24-week of pegylated-interferon-alfa-2b.
Persistent Identifierhttp://hdl.handle.net/10722/108022
ISSN
2014 Impact Factor: 3.504
2014 SCImago Journal Rankings: 1.128

 

DC FieldValueLanguage
dc.contributor.authorLai, LSWen_HK
dc.contributor.authorFung, TTen_HK
dc.contributor.authorLai, STen_HK
dc.contributor.authorYiu, Jen_HK
dc.contributor.authorLam, Pen_HK
dc.contributor.authorZhang, Hen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorHui, CKen_HK
dc.contributor.authorLeung, Nen_HK
dc.contributor.authorLau, Gen_HK
dc.date.accessioned2010-09-26T00:22:12Z-
dc.date.available2010-09-26T00:22:12Z-
dc.date.issued2006en_HK
dc.identifier.citationShanghai—Hong Kong International Liver Congress, Shanghai, China, 25–28 March 2006. In Journal of Gastroenterology and Hepatology, 2006, v. 21 n. S2, p. A90en_HK
dc.identifier.issn0815-9319-
dc.identifier.urihttp://hdl.handle.net/10722/108022-
dc.description.abstractBackground/Aim Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronichepatitis B virus (HBV) infection, the efficacy of a shorter durationof therapy with pegylated interferons is unknown.Method We retrospectively compared the efficacy of 48 weeks treat-ment with pegylated-interferon-alfa-2a to a 24-week regime withpegylated-interferon-alfa-2b in 53 hepatitis B e antigen (HBeAg) positive Chinese patients. Sustained virological response (SVR) wasdefined as HBeAg seroconversion and HBV DNA less than 105copies/ml at 24 weeks after the end-of-therapy (EFU).Results Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alfa-2a and 24 patients with 24 weeks of pegylated-interferon-alfa-2b. The baseline characteristics were com-parable between the 2 groups. At the end-of-therapy, 9 of the 29patients (31.0%) treated with 48 weeks of pegylated-interferon-alfa-2a compared with 2 of the 24 patients (8.3%) treated with 24weeks of pegylated-interferon-alfa-2b had HBeAg seroconversion andHBV DNA less than 105 copies/ml (p = 0.09). At the EFU, 10 of the29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alfa-2a compared with 2 of the 24 patients (8.3%) treated with 24weeks of pegylated-interferon-alfa-2b had SVR (p = 0.04). There wasno withdrawals from treatment in both groups. Adverse events werecomparable between the 2 groups.Conclusion A 48-week course of pegylated-interferon may be asso-ciated with a higher SVR when compared with 24-week of pegylated-interferon-alfa-2b.-
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH-
dc.publisherWiley-Blackwell Publishing Asia-
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.title48 Weeks pegylated interferon alfa-2a is superior to 24 weeks of pegylated interferon alfa-2b in achievingHBeAg seroconversion in chronic hepatitis B infectionen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailZhang, H: hying64@hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailHui, CK: ckh23@cam.ac.uken_HK
dc.identifier.emailLau, G: gkklau@netvigator.comen_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1746.2006.04405.x-
dc.identifier.hkuros117040en_HK
dc.identifier.hkuros121884-
dc.identifier.volume21en_HK
dc.identifier.issueSuppl. 2en_HK
dc.identifier.spage90en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats